TY - JOUR
T1 - Outcomes after stereotactic body radiotherapy versus limited resection in older patients with early-stage lung cancer
AU - Ezer, Nicole
AU - Veluswamy, Rajwanth R.
AU - Mhango, Grace
AU - Rosenzweig, Kenneth E.
AU - Powell, Charles A.
AU - Wisnivesky, Juan P.
N1 - Publisher Copyright:
Copyright © 2015 by the International Association for the Study of Lung Cancer.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Background: Limited resection and stereotactic body radiotherapy (SBRT) have emerged as treatment options for older patients with early-stage non-small-cell lung cancer (NSCLC), who are not good candidates for lobectomy. Methods: We used the Surveillance, Epidemiology and End Results- Medicare registry to identify patients older than 65 years with stage I to II NSCLC and negative lymph nodes treated with SBRT versus limited resection. We fitted a propensity score model predicting the use of SBRT and compared adjusted overall survival of patients treated with SBRT versus limited resection. Secondary analyses stratified the sample by type of limited resection (wedge versus segmentectomy), age (≤75 versus >75 years), and tumor size (<3 versus ≥3 cm). We also compared rates of surgical complications and SBRTrelated toxicity in the two groups. Results: We identified 2243 patients of which 362 (16%) patients received SBRT. SBRT-treated patients were older, had higher comorbidity scores, and had larger tumors (p < 0.001 for all comparisons). Adjusted analyses showed no differences in survival (hazard ratio [HR], 1.19; 95% confidence interval [CI], 0.97-1.47) among patients treated with SBRT versus limited resection. Although survival of patients who underwent SBRT versus wedge resection was not different (HR, 1.22; 95% CI, 0.98-1.52), SBRT was associated with worse outcomes when compared with segmentectomy (HR, 1.55; 95% CI, 1.18-2.03). Adverse events were most often respiratory and more frequent in the patients treated with limited resection (28% versus 14%, p < 0.001). Conclusion: SBRT is better tolerated and associated with similar survival when compared with wedge resection but not with segmentectomy in older patients with node-negative NSCLC.
AB - Background: Limited resection and stereotactic body radiotherapy (SBRT) have emerged as treatment options for older patients with early-stage non-small-cell lung cancer (NSCLC), who are not good candidates for lobectomy. Methods: We used the Surveillance, Epidemiology and End Results- Medicare registry to identify patients older than 65 years with stage I to II NSCLC and negative lymph nodes treated with SBRT versus limited resection. We fitted a propensity score model predicting the use of SBRT and compared adjusted overall survival of patients treated with SBRT versus limited resection. Secondary analyses stratified the sample by type of limited resection (wedge versus segmentectomy), age (≤75 versus >75 years), and tumor size (<3 versus ≥3 cm). We also compared rates of surgical complications and SBRTrelated toxicity in the two groups. Results: We identified 2243 patients of which 362 (16%) patients received SBRT. SBRT-treated patients were older, had higher comorbidity scores, and had larger tumors (p < 0.001 for all comparisons). Adjusted analyses showed no differences in survival (hazard ratio [HR], 1.19; 95% confidence interval [CI], 0.97-1.47) among patients treated with SBRT versus limited resection. Although survival of patients who underwent SBRT versus wedge resection was not different (HR, 1.22; 95% CI, 0.98-1.52), SBRT was associated with worse outcomes when compared with segmentectomy (HR, 1.55; 95% CI, 1.18-2.03). Adverse events were most often respiratory and more frequent in the patients treated with limited resection (28% versus 14%, p < 0.001). Conclusion: SBRT is better tolerated and associated with similar survival when compared with wedge resection but not with segmentectomy in older patients with node-negative NSCLC.
KW - Non-small-cell lung cancer
KW - Radiosurgery.
KW - Radiotherapy
KW - Segmentectomy
KW - Wedge resection
UR - http://www.scopus.com/inward/record.url?scp=84942857253&partnerID=8YFLogxK
U2 - 10.1097/JTO.0000000000000600
DO - 10.1097/JTO.0000000000000600
M3 - Article
C2 - 26200275
AN - SCOPUS:84942857253
SN - 1556-0864
VL - 10
SP - 1201
EP - 1206
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 8
ER -